Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage

BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he/she will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.

NCT Number	NCT07243704
Lead Sponsor	Christian Medical College and Hospital, Ludhiana, India Collaborators: Indian Council of Medical Research, St. Stephen's Hospital, Delhi, Amrita Institute of Medical Sciences & Research Center, Kasturba Medical College, Bangur Institute of Neurosciences Kolkata, Baptist Christian Hospital, Tezpur, India, Christian Medical College, Vellore, India, Lalitha Super Specialities Hospital, Dr. Ramesh Cardiac and Multispecialty Hospital Guntur, India, Government General Hospital Guntur, India, Institute of Medical Sciences of the Banaras Hindu University, India, All India Institute of Medical Sciences, Bhubaneswar, KLE'S Dr Prabhakar Kore Hospital & MRC Balgaum, Guru Gobind Singh Medical College & Hospital, PBM Hospital Bikaner, India, Excelcare Hospitals Guwahati, Bharati Vidyapeeth DTU Medical College Pune, India, All India Institute of Medical Sciences, Bilaspur, KG Hospital and Post Graduate Medical Institute Coimbatore, India, Tirunelveli Medical College, Tirunelveli, India, Santokba Durlabhji Memorial Hospital, Institute of Human Behaviour and Allied Sciences Delhi, Government Medical College Trivandrum, India, Jaiswal Multispeciality Hospital And Neuro Institute, Kota, Shri Maharaja Hari Singh Hospital, Government Medical College, Anantnag, India, Narayana Medical College & Hospital, Renova Institute of Neurological Sciences (RINS); Renova Century Hospital Hyderabad, Rangaraya Medical College, All India Institute of Medical Sciences, Raebareli, UP, All India Institute of Medical Science, Patna, Bihar, India, Sri Balaji Institute of Medical Sciences, Raipur, Chhattisgarh, India, Manipal Group of Hospitals (Eastern Region), Kolkata, India, Sree Chitra Tirunal Institute for Medical Sciences & Technology, All India Institute of Medical Science, Guwahati, All India Institute of Medical Science, New Delhi, King George's Medical University, Lucknow, India, P. D. Hinduja Hospital and Medical Research Centre, KIMS-SUNSHINE Hospital, Hyderabad, India, Sahyadri Superspeciality Hospital, Nasik, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
Conditions	Intracerebral Haemorrhage
Enrollment	5,676 participants
Start Date	2026-02-15
Primary Completion	2029-02-14 (estimated)
Study Completion	2029-02-14 (estimated)
Updated on ClinicalTrials.gov	2026-02-09